Study of Tissue Collection and Disease Progression in Patients with Malignant Mesothelioma and Other Cancers Expressing Mesothelin

What this Trial Is About

Malignant mesothelioma is a cancer originating from mesothelial cells in areas such as the pleura and peritoneum, accounting for a small percentage of deaths annually in the United States. This condition, especially pleural mesothelioma, often presents at advanced stages with limited treatment options. The study also focuses on other cancers that express mesothelin, including thymic carcinoma, pancreatic, biliary, lung, gastric, and ovarian cancers, aiming to collect samples for research purposes. Participants include those aged 2 years and older with malignant mesothelioma and those 18 years and older with other mesothelin-expressing cancers. The study involves collecting samples of blood, urine, tumor tissue, and abnormal body fluids for tissue banking. These samples will support various research activities such as genetic and genomic studies, cell culture establishment, and immunologic analysis. During the study, participants will be followed to observe the course of their disease and any treatments they receive. The research team will collect and store biological samples to advance understanding of mesothelioma and related cancers. The primary outcome is ongoing sample acquisition. Participation may last several years as the disease course is monitored, with no intervention or treatment provided as part of this observational study.

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma